Literature DB >> 22490447

Inhibitory role of kinins on microglial nitric oxide and tumor necrosis factor-α production.

Ben-Shmuel Sarit1, Gera Lajos, Danon Abraham, Apte Ron, Fleisher-Berkovich Sigal.   

Abstract

Brain inflammation is sustained by chronic activation of microglia and the over-production of pro-inflammatory cytokines and nitric oxide (NO), which in turn can be highly neurotoxic. Microglial activation can be regulated by neuropeptides such as bradykinin (BK) and other members of the kinin family. Kinins are well known inflammatory regulators outside the CNS. Although the kinin system is well distributed throughout the brain, the precise role of BK in the CNS is not yet clear. The aim of this study was to examine and characterize the effects of BK and related kinins on the production of NO and TNF-α in microglia. We found that BK and selective agonists for both B1 and B2 receptors, attenuated both NO and TNF-α levels in the media of BV2 microglial cells that had been stimulated with LPS. The effects of BK that were observed in BV2 cells were confirmed in primary neonatal rat microglial cells as well. In addition, all kinin agonists reduced the expression of iNOS and TNF-α protein and mRNA levels in LPS-stimulated BV2 cells. Also, while LPS activated the nuclear factor-κB (NF-κB) pathway, BK inhibited NF-κB activation by preventing degradation of the κB protein (IκB) inhibitor, abolishing translocation of p65 and p50 subunits to the nucleus and inhibiting NF-κB transcription activity. These results suggest a role for bradykinin in modulation of glial inflammation, as evidenced by attenuation of NO and TNF-α synthesis pathways in activated microglial cells.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22490447     DOI: 10.1016/j.peptides.2012.03.026

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  8 in total

Review 1.  Involvement of bradykinin in brain edema development after ischemic stroke.

Authors:  Marina Dobrivojević; Katarina Špiranec; Aleksandra Sinđić
Journal:  Pflugers Arch       Date:  2014-04-23       Impact factor: 3.657

Review 2.  Immunomodulation in stem cell differentiation into neurons and brain repair.

Authors:  Henning Ulrich; Isis Cristina do Nascimento; Jozsef Bocsi; Attila Tárnok
Journal:  Stem Cell Rev Rep       Date:  2015-06       Impact factor: 5.739

3.  A Comparative In Vitro Study on the Antioxidant and Anti-acetylcholinesterase Properties of Aerial Parts of Strophanthus preusii Engl & Pax.

Authors:  O A Adaramoye; A Olajuyin
Journal:  West Indian Med J       Date:  2014-07-03       Impact factor: 0.171

Review 4.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.

Authors:  Amaly Nokkari; Hadi Abou-El-Hassan; Yehia Mechref; Stefania Mondello; Mark S Kindy; Ayad A Jaffa; Firas Kobeissy
Journal:  Prog Neurobiol       Date:  2018-01-31       Impact factor: 11.685

5.  Involvement of the Bradykinin B1 Receptor in Microglial Activation: In Vitro and In Vivo Studies.

Authors:  Keren Asraf; Nofar Torika; Abraham Danon; Sigal Fleisher-Berkovich
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-19       Impact factor: 5.555

6.  The Dual Role of Kinin/Kinin Receptors System in Alzheimer's Disease.

Authors:  Bingyuan Ji; Qinqin Wang; Qingjie Xue; Wenfu Li; Xuezhi Li; Yili Wu
Journal:  Front Mol Neurosci       Date:  2019-10-01       Impact factor: 5.639

7.  Activated microglia provide a neuroprotective role by balancing glial cell-line derived neurotrophic factor and tumor necrosis factor-α secretion after subacute cerebral ischemia.

Authors:  Jianping Wang; Zhitang Yang; Cong Liu; Yuanzheng Zhao; Yibing Chen
Journal:  Int J Mol Med       Date:  2012-11-13       Impact factor: 4.101

8.  Telmisartan Modulates Glial Activation: In Vitro and In Vivo Studies.

Authors:  Nofar Torika; Keren Asraf; Abraham Danon; Ron N Apte; Sigal Fleisher-Berkovich
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.